At least one published case of incident (breakthrough) HIV-1 infection in an individual receiving twice-yearly lenacapavir PrEP per protocol, with documented capsid-gene resistance-associated mutation (Q67H/K, N74D, M66I, K70N, T107N/A, or similar), will be reported within 180 days of LEN PrEP rollout expansion (post-FDA approval Jun 2025, PEPFAR+GF investment Apr 2026).

System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.

Moderate confidence

Confidence in this assessment

40%

The evidence is meaningful, but there is still material uncertainty. Based on 0 linked evidence items and assessed against P180D.

Assessed through P180D0 linked evidence itemsTracking since Apr 18, 2026

How this assessment will be evaluated

The criteria the system uses to determine whether this assessment is borne out by the stated horizon.

Automated

Method

Evidence Match

The condition the system checks for when evaluating this assessment.

Minimum source quality

T1Primary Institutional

Evidence must meet or exceed this credibility tier to count toward evaluation.

Required terms

resistance-associatedbreakthroughtwice-yearlylenacapavir

Evidence quality mix

Tracking since Apr 18, 2026.

Integrity referencesCryptographic hashes for verification

Registration

Integrity anchor

Brier 0.202

19 resolved novel pathogen detection predictions.

Scope synthesis

The current analyst narrative for this scope.

Open synthesis →

HIV/AIDS evidence pipeline at lowest coverage across all scopes this cycle; all connectors stale or failing; PEPFAR litigation and SSA program impact hypotheses remain open without new data.

No LEN breakthrough case report published

Evidence linked to this assessment

0 linked items.

No linked evidence is available for this assessment yet.